Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China

Diagnostic Pathology

Jianhua Li²  Xiangmin He⁴  Changqing Fang²  Changsi Li⁵  Yi Lou⁶  Deguang Wang³  Qingbin Song¹ 

[1] Department of general surgery, The First affiliated hospital, China Medical University (Nanjing North Street), Shenyang (110001), China;Department of pathology, The First affiliated hospital, China Medical University (Nanjing North Street), Shenyang (110001), China. Department of pathology, China Medical University (North 2. Road), Shenyang (110001), China;Department of Magnetic Resonance Imaging, No. 404 Hospital of People's Liberation Army (Baoquan Road), Weihai (264200), China;Department of digestive medicine, The First affiliated hospital, China Medical University (Nanjing North Street), Shenyang (110001), China;Department of rehabilitation, The First affiliated hospital, China Medical University (Nanjing North Street), Shenyang (110001), China;Department of genetics, China Medical University (North 2. Road), Shenyang (110001), China

关键词: galectin-3;    Ki67;    TG;    CK19;    Papillary thyroid carcinoma;   

Others  :  808183
DOI  :  10.1186/1746-1596-6-126

 received in 2011-10-27, accepted in 2011-12-21,  发布年份 2011

【 摘 要 】

Background

To evaluate the expression and differential diagnostic significance of CK19, TG, Ki67 and galectin-3 in papillary thyroid carcinoma (PTC) (metastatic and non metastatic), follicular adenoma and nodular goiter in patients from the northeastern part of China.

Methods

441 PTC specimens and 151 other benign thyroid specimens (97 cases of nodular goiter, 54 cases of nonmalignant follicular adenoma) were collected. Immunohistochemistry for CK19, TG, Ki67 and galectin-3 was performed.

Results

CK19, TG, Ki67 and galectin-3 expression was 96.37% (425/441), 82.77% (365/441), and 40.59% (179/441), 96.82% (427/441), respectively, for the PTC group and the expression of these markers in the benign thyroid lesions group was 25.83% (39/151), 79.47% (120/151), and 37.09% (56/151), 50.99% (77/151), respectively. The expression of CK19 and galectin-3 in PTC was much higher than that in the nonmalignant group (p < 0.05). However, the expression of TG, Ki67 did not differ among these two groups (p > 0.05). The diagnostic efficiency of CK19 and galectin-3 for PTC was 96.37% (537/592) and 84.63% (501/592). CK19 and galectin-3 expression rate in PTC was higher than that in benign disease cases.

Conclusions

The diagnostic efficiency of CK19 for PTC was slightly better than galectin-3. The utilization of these markers combined with morphologic evaluation may be helpful in the differential diagnosis of papillary thyroid carcinoma in the northeastern region of China.

【 授权许可】

   
2011 Song et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Nikiforov YE: Thyroid tumors: classification and general considerations. In Diagnostic Pathology and Molecular Genetics of the Thyroid. Edited by Nikiforov YE, Biddinger PW, Thompson LDR. Lippincott Williams & Wilkins, Baltimore, MA; 2009:94-102.
• [2]DeVita VT, Hellman JS, Rosenberg SA: Cancer: principles and practice of oncology. Lippincott Williams & Wilkins 2008, 1674-1699.
• [3]Sethi K, Sarkar S, Das S, Mohanty B, Mandal M: Biomarkers for the diagnosis of thyroid cancer. J Exp Ther Oncol 2010, 8:341-352.
• [4]Kato MA, Fahey TJ: Molecular markers in thyroid cancer diagnostics. Surg Clin North Am 2009, 89:1139-1155.
• [5]Nikiforov YE: Molecular analysis of thyroid tumors. Mod Pathol Suppl 2011, 2:34-43.
• [6]Ito Y, Miyauchi A, Kakudo K, Hirokawa M, Kobayashi K, Miya A: Prognostic significance of ki-67 labeling index in papillary thyroid carcinoma. World J Surg 2010, 34:3015-21.
• [7]Vierlinger K, Mansfeld MH, Koperek O, Nöhammer C, Kaserer K, Leisch F: Identification of SERPINA1 as single marker for papillary thyroid carcinoma through microarray meta analysis and quantification of its discriminatory power in independent validation. BMC Med Genomics 2011, 6;4:30.
• [8]Tan A, Etit D, Bayol U, Altinel D, Tan S: Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma. Ann Diagn Pathol 2011, 15:108-116.
• [9]Fryknäs M, Wickenberg-Bolin U, Göransson H, Gustafsson MG, Foukakis T, Lee JJ, Landegren U, Höög A, Larsson C, Grimelius L, Wallin G, Pettersson U, Isaksson A: Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumour Biol 2006, 27:211-220.
• [10]Magro G, Cataldo I, Amico P, Torrisi A, Vecchio GM, Parenti R, Asioli S, Recupero D, D'Agata V, Mucignat MT, Perris R: Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target. Thyroid 2011, 21:267-277.
• [11]Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, Nabi IR, Wiseman SM: Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010, 176:2067-2081.
• [12]Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO: Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol 2010, 21:80-89.
• [13]Park YJ, Kwak SH, Kim DC, Kim H, Choe G, Park do J, Jang HC, Park SH, Cho BY, Park SY: Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27 (kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci 2007, 22:621-628.
• [14]El Demellawy D, Nasr A, Alowami S: Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol 2008, 3:5. BioMed Central Full Text
• [15]Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT: Galectin-3, fibronectin-1, CITED-1, HBME-1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 2005, 18:48-57.
• [16]de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpção LV, Metze K, Ward LS: Usefulness of HBME-1, cytokeratin-19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 2005, 47:391-401.
• [17]Cattoretti G, Becker MH, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed for malin-fixed paraffin sections. J Pathol 1992, 168:357-363.
• [18]Saiz AD, Olvera M, Rezk S, Florentine BA, McCourty A, Brynes RK: Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. J Pathol 2002, 198:157-162.
• [19]Liang HS, Zhong YH, Luo ZJ, Huang Y, Lin HD, Luo M, S-Zhan Su HX, Zhou SB, Xie KQ: Comparative analysis of protein expression in differentiated thyroid tumours: a multicentre study. J Int Med Res 2009, 37:927-938.
• [20]Carpi A, Mechanick JI, Saussez S, Nicolini A: Thyroid tumor marker genomics and proteomics: diagnostic and clinical implications. J Cell Physiol 2010, 224:612-619.
• [21]Lazar V, Bidart JM, Caillou B, Mahé C, Lacroix L, Filetti S, Schlumberger M: Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 1999, 84:3228-3234.
• [22]Martins L, Matsuo SE, Ebina KN, Kulcsar MA, Friguglietti CU, Kimura ET: Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab 2002, 87:4806-4810.
• [23]Raimond J, Zimonjic DB, Mignon C, Mattei M, Popescu NC, Monsigny M, Legrand A: Mapping of the galectin-3 gene (LGALS3) to human chromosome 14 at region 14q21-22. Mamm Genome 1997, 8:706-707.
• [24]Türköz HK, Oksüz H, Yurdakul Z, Ozcan D: Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr Pathol 2008, 19:92-96.
• [25]Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, De Giuli P, Angeli A: Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 1998, 58:3015-3020.
• [26]Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S, Sueyoshi K, Aikou T, Sato E: Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 2000, 31:428-433.
• [27]Kovàcs RB, Földes J, Winkler G, Bodó M, Sápi Z: The investigation of galectin-3 in diseases of thyroid gland. Eur J Endocrinol 2003, 149:449-453.
• [28]Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R, Larsson O: Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001, 357:1644-1650.
• [29]Erkiliç S, Aydin A, Koçer NE: Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid. Endocr Pathol 2002, 13:207-211.
• [30]Fonseca E, Nesland JM, Höie J, Sobrinho-Simões M: Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of simple and stratified epithelial-type cytokeratins. Virchows Arch 1997, 430:239-245.
• [31]Prasad ML, Huang Y, Pellegata NS, de la Chapelle A, Kloos RT: Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC) - like nuclear alterations expresses molecular markers of PTC. Histopathology 2004, 45:39-46.
• [32]Rossi ED, Raffaelli M, Mule' A, Miraglia A, Lombardi CP, Vecchio FM, Fadda G: Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology 2006, 48:795-800.
• [33]Schelfhout LJ, Van Muijen GN, Fleuren GJ: Expression of keratin 19 distinguishes papillary thyroid carcinoma from follicular carcinomas and follicular thyroid adenoma. Am J Clin Pathol 1989, 92:654-658.